Castor Oil Pharmaceutical USP/EP (Pharmacopeial Cold-Pressed Ricinus communis Seed Oil) Storage

Castor Oil Pharmaceutical USP/EP (Pharmacopeial-Grade Cold-Pressed Ricinus communis Seed Oil) Storage — Compendial Castor Oil + Polyoxyl-35-Castor-Oil Tank Selection at Pharmaceutical, Oncology IV-Solvent, and Compounding-Pharmacy Operations

Castor Oil Pharmaceutical USP (also called pharmaceutical castor oil, ricinus oil, palma christi oil; CAS 8001-79-4; Ricinus communis seed oil; triglyceride mixture dominated by ricinoleic-acid esters) is a clear, pale-yellow, viscous, fixed (non-drying) vegetable triglyceride oil obtained by cold-pressing of Ricinus communis (castor bean) seeds and meeting the USP-43-NF-38 Castor Oil monograph and Ph. Eur. 11.0 Refined Castor Oil monograph. The triglyceride profile is dominated by ricinoleic acid (12-hydroxy-octadec-9-enoic acid) at 85-92% of total fatty acids, with smaller fractions of oleic (3-7%), linoleic (3-5%), palmitic (1-2%), and stearic (1-2%); the high ricinoleate content is unique among commercially available oils and gives castor oil its characteristic combination of high viscosity (985 cP at 20°C, vs. 35-50 cP for soybean and corn oils), high specific gravity (0.957-0.961 vs. 0.91-0.92 for most vegetable oils), high hydroxyl value (160-168 mg KOH/g), and unusual chemical reactivity at the hydroxyl group on the C12 carbon enabling chemical-modification chemistry (sulfated castor oil "Turkey Red Oil," polyoxyl-35-castor-oil "Cremophor EL," polyoxyl-40-hydrogenated-castor-oil, dehydrated castor oil for paint resins).

Pharmaceutical USP castor oil functions as oral stimulant laxative API (the historic primary pharmaceutical use; FDA OTC monograph laxative active at 15-60 mL adult dose), ophthalmic emollient + lubricant in artificial-tear preparations (Restasis cyclosporine ophthalmic emulsion uses castor oil as lipid-phase carrier), iconic IV-injectable solvent for poorly-water-soluble oncology drugs (paclitaxel injection Taxol uses Polyoxyl-35-castor-oil [Cremophor EL] as cosolvent + miscibility agent at 50% v/v in formulation), suppository plasticizer + base + emollient component, capsule-shell plasticizer in soft-gel manufacturing, and topical emollient + cosmetic active. Physical properties: density 0.957-0.961 g/cm³ at 25°C; specific gravity 0.957-0.961; viscosity 985 cP at 20°C dropping to 240 cP at 50°C; flash point 229°C closed cup; autoignition 449°C; iodine value 83-88; saponification value 176-184; acid value under 2.0; hydroxyl value 160-168; refractive index 1.477-1.481 at 25°C; melting point -10 to -18°C; immiscible with water (forms two-phase emulsion); fully soluble in absolute ethanol, ether, glacial acetic acid; partially soluble in light petroleum ether.

The eight sections below cite USP-NF 43, Ph. Eur. 11.0, JP 18, FDA 21 CFR Parts 210 + 211 + 600-680, USP <401> Fats and Fixed Oils, USP <731> Loss on Drying, USP <921> Water Determination, USP <1116> Microbial Bioburden, ASME BPE-2022, ICH Q3D + Q3C + Q7 + Q9 + Q10, FDA OTC Monograph 21 CFR 334.20 Stimulant Laxatives, and operating practice at Acme-Hardesty (castor oil + derivatives), Jayant Agro Organics (India, world's leading castor oil refiner), Adani Wilmar, ITOH Oil Chemicals (Japan), Penreco (Calumet), and pharmaceutical manufacturing operations at Bristol Myers Squibb (Taxol historical), Allergan + AbbVie (Restasis), Hospira / Pfizer (paclitaxel + cyclosporine generics), Sandoz (paclitaxel generic), Padagis, Perrigo OTC for compendial castor-oil storage and dispensing.

1. Material Compatibility Matrix

Pharmaceutical USP castor oil is a chemically gentle plant-derived triglyceride with no oxidizer character, no acid character (acid value under 2.0), no halogen or sulfur species, and unique hydroxyl-group reactivity at the C12 of ricinoleate. Material selection mirrors mineral oil USP closely; the high viscosity drives ambient-temperature pumping considerations.

The dominant industrial pattern at pharmaceutical castor-oil-using manufacturing is HDPE bulk-receipt at the ingredient warehouse for ambient-temperature staging (working-stock turnover under 6 months acceptable) followed by 316L electropolished sanitary stainless formulation vessels for product-contact preparation. Heated bulk-storage (above 50°C) is best served by stainless rather than HDPE due to the long-term oil-swell concern. OneSource Plastics' 5-brand HDPE network covers the bulk-receipt + raw-material-warehouse + compounding-pharmacy + ambient-temperature non-product-contact short-term ingredient-storage envelope; ASME BPE 316L sanitary stainless tanks for product-contact ophthalmic + IV-injectable + suppository + oral formulation are outside the HDPE scope.

2. Real-World Industrial Use Cases

Oncology IV-Solvent for Paclitaxel. Polyoxyl-35-castor-oil (Cremophor EL, Kolliphor EL when produced by BASF) is the principal cosolvent in IV paclitaxel injection (Taxol, original Bristol Myers Squibb formulation; multiple paclitaxel generics including Hospira / Pfizer + Sandoz + Sun Pharma + Teva) at 50% v/v in formulation combined with dehydrated alcohol USP at 50% v/v. The Cremophor-EL-based formulation enables IV administration of an extremely water-insoluble taxane chemotherapy active; the formulation is associated with hypersensitivity reactions requiring premedication with corticosteroids + H1 + H2 antihistamines. The Cremophor-free reformulation of paclitaxel (Abraxane, albumin-bound paclitaxel; Bristol Myers Squibb) avoids the castor-oil-derivative entirely and addresses the hypersensitivity issue. Other oncology actives historically formulated in Cremophor EL: cyclosporine (Sandimmune) and docetaxel (Taxotere; Polysorbate-80 + ethanol).

Restasis Ophthalmic Cyclosporine Emulsion. Restasis cyclosporine ophthalmic emulsion 0.05% (Allergan / AbbVie) uses castor oil USP at 1.25% w/v as the lipid-phase carrier of cyclosporine in a two-phase oil-in-water ophthalmic emulsion stabilized with polysorbate-80. The castor oil provides solubilization of the lipophilic cyclosporine + lipid-restoration of the tear-film outer layer in chronic dry-eye disease. Manufacturing requires sterile, low-bioburden, low-endotoxin, low-particulate USP castor oil per USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter, USP <789> ophthalmic-particulate-matter testing.

Oral Stimulant Laxative API. USP castor oil is included in OTC oral stimulant laxative preparations under FDA 21 CFR 334.20 OTC Monograph: Castor Oil 100% (Humco, Padagis), Cumberland Pharmaceuticals castor oil; multiple generic + house-brand oral castor oil products. Adult dose 15-60 mL inducing intestinal stimulation via ricinoleic-acid-mediated prostaglandin EP3-receptor activation in intestinal smooth-muscle. Manufacturing at Humco, Heritage Pharmaceuticals, Padagis, Perrigo OTC.

Soft-Gel Capsule Shell + Plasticizer. Hydrogenated castor oil + polyoxyl-40-hydrogenated-castor-oil are used as soft-gel capsule shell plasticizer + capsule-fill emulsifier in oral soft-gelatin + soft-shell capsule manufacturing across vitamins, dietary supplements, and prescription pharmaceuticals (testosterone undecanoate Andriol, cyclosporine Neoral). Soft-gel manufacturing at Catalent (largest global soft-gel manufacturer), Patheon, IFE Pharma, Sirio Pharma, Aenova.

Suppository Base + Plasticizer. USP castor oil + hydrogenated castor oil function as plasticizer + emollient in suppository base formulations alongside cocoa butter, mineral oil, petrolatum, and PEG bases. Inclusion 5-20% w/w in suppository base. Manufacturing at Ferring Pharmaceuticals, Catalent, Padagis, Perrigo.

Topical + Cosmetic Emollient. USP castor oil is included in topical OTC + dermatologic + cosmetic formulations as emollient + occlusive: hair-care leave-in oil treatments, lip-balm bases, beard-grooming oils, eyelash-care preparations, scalp-treatment oils. Inclusion 5-100% (in dedicated castor-oil-only treatments). Manufacturing at L'Oreal, Beiersdorf, Procter & Gamble Beauty, Unilever Personal Care, Burt's Bees (Clorox).

Compounding Pharmacy Working Stocks. 503A + 503B compounding operations stock USP castor oil in 1-pint to 55-gallon to 275-gallon IBC tote sizes for use in patient-specific topical, suppository, and oral compounded preparations under USP <795> non-sterile compounding standards.

3. Regulatory Hazard Communication

OSHA HazCom GHS Classification. USP pharmaceutical castor oil is not classified as a GHS hazardous substance. Flash point 229°C closed cup places it well above the Class IIIB combustible-liquid threshold; not flammable in normal handling. No GHS health-hazard classifications at oral, dermal, or inhalation routes (extensive feeding-study + dermal + inhalation safety testing places castor oil at GRAS for food + cosmetic use; pharmaceutical use as oral stimulant laxative is FDA-approved under OTC monograph). Important toxicology note: castor seeds contain ricin, a highly toxic ribosome-inactivating protein; ricin is removed during the cold-pressing + acid-degumming + bleaching + deodorizing refinement of pharmaceutical castor oil. Pharmaceutical USP castor oil is ricin-free; ricin contamination has never been documented in pharmaceutical-grade castor oil meeting compendial specifications. Environmental: rapidly biodegradable; fish LC₅₀ over 5000 mg/L. H-statements: typically none required.

FDA cGMP Compliance Framework. Pharmaceutical USP castor oil used in finished drug products is regulated under 21 CFR Part 210 + 211 (finished pharmaceuticals) and 21 CFR Parts 600-680 (biologics). Identity testing per 21 CFR 211.84(d)(2) requires at least one specific identity test on each container received; USP identification by IR spectrum + specific gravity + refractive index + iodine value + saponification value + hydroxyl value are the standard pharmacopeial identity panel. ICH Q7 GMP for active pharmaceutical ingredients applies when castor oil is used as oral laxative API; ICH Q3D + Q3C apply to elemental + residual-solvent impurities. ICH Q5A viral safety considerations do not apply (plant-derived material).

USP-NF 43 Compendial Specifications. Pharmacopeial harmonized castor oil specifications: identification by refractive index 1.477-1.481 at 25°C + specific gravity 0.957-0.961 at 25°C + IR spectrum + saponification value 176-184 + hydroxyl value 160-168 + iodine value 83-88 + acid value under 2.0; loss on drying under 1.0%; alkaline impurities (faint pink color limit per USP test); foreign oils (limit per saponification/iodine ratio); arsenic under 2 ppm; heavy metals under 5 ppm; ICH Q3D elemental impurities; ICH Q3C residual solvents (no organic solvent used in pharmaceutical castor oil manufacture; cold-pressed without solvent extraction).

DOT and Shipping. USP castor oil is not regulated under 49 CFR DOT Hazardous Materials Regulations. No UN number, no hazard class, no packing group. Shipped as standard non-hazardous fixed oil in HDPE drums (5-30-55-gallon), HDPE 275-330-gallon IBC totes, and stainless or HDPE-lined tank trucks (4500-6500 gallon delivery for bulk pharmaceutical-feedstock movements).

EPA Air Regulations. Castor oil storage tanks not subject to 40 CFR Part 60 NSPS Subpart Kb (vapor pressure under 0.001 psi at room temperature); not subject to Subpart K, KKK, or similar air regulations. Pharmaceutical manufacturing facilities subject to 40 CFR Part 63 Subpart GGG NESHAP for organic HAPs; castor oil not a HAP.

FDA Food + Cosmetic Authorization. Castor oil holds GRAS status per FDA 21 CFR 184.1620 (direct human food additive affirmed GRAS) for limited food-additive use as flavor + carrier + release-agent; cosmetic-ingredient status per FDA cosmetic regulations + CIR (Cosmetic Ingredient Review) safety panel review. EU cosmetic-ingredient authorization under Cosmetics Regulation (EC) 1223/2009.

4. Storage System Specification

Bulk-Receipt and Raw-Material-Warehouse Storage. Pharmaceutical USP castor oil arrives at the manufacturing facility raw-material warehouse via 5-gallon pails, 30-55-gallon HDPE drums, 275-330-gallon HDPE IBC totes, or stainless or HDPE-lined tank trucks (4500-6500 gallon delivery). Bulk-tanker deliveries at large pharmaceutical operations transfer to dedicated bulk-receipt storage tanks: HDPE rotomolded vertical 1500-15000-gallon vessels at ambient-temperature service, FDA-grade HDPE-blend per 21 CFR 177.1520 with sanitary fittings + atmospheric vent with hydrophobic dust filter + tank-mounted level transmitter (radar or guided-wave). Castor oil's high viscosity (985 cP at 20°C) makes ambient-temperature transfer slower than for low-viscosity polyols; some operations include modest tank-jacket warming (35-45°C) to reduce viscosity to 300-500 cP for faster transfer.

Tank Sizing. Typical bulk-receipt tank sizes: 1500-3000 gallons at compounding pharmacies + small-batch oncology-IV-fill operations; 5000-10000 gallons at mid-size pharmaceutical manufacturing; 15000-30000 gallons at large-scale dermatologic + ophthalmic + soft-gel-encapsulation operations.

Compounding Pharmacy Working-Stock Storage. Compounding pharmacies + 503A + 503B operations stock USP castor oil in 5-30 gallon HDPE drums + 1-5 gallon working-stock containers at the ingredient warehouse + sterile + non-sterile compounding cleanroom. Drum + tote receiving uses HDPE-pump dispensing into smaller working stocks; working stocks dispensed from FDA-grade HDPE bottles.

Product-Contact Formulation Tanks. Active formulation + compounding for finished oral / ophthalmic / IV-injectable / suppository / soft-gel preparations occurs in 316L electropolished sanitary stainless tanks per ASME BPE-2022 with internal surface finish Ra under 0.5 microns, all-welded 316L sanitary tri-clamp transfer piping, BPE diaphragm or ball valves, jacketed temperature control (often heated to 50-70°C to reduce viscosity for emulsion + suppository-base preparation), top-mounted impeller agitation, CIP/SIP capability via hot-water + saponifier cleaning cycles.

Secondary Containment. Bulk-receipt castor-oil storage vessels at pharmaceutical operations are placed inside HDPE secondary-containment pans sized to 110% of largest single tank capacity per facility-wide containment best-practice. Castor oil is not regulated as an EPA oil under SPCC (vegetable oils above 1320 gallons are explicitly subject to SPCC if facility aggregate exceeds; vegetable-oil SPCC is a lower-impact regulatory framework than petroleum-oil SPCC but still triggers facility containment + spill-response planning).

Inert-Gas Blanketing. Pharmaceutical-grade castor oil bulk storage at high-end sterile-fill + IV-injectable + ophthalmic-emulsion operations may include nitrogen blanketing of the tank vapor space to minimize peroxide formation + oxidative rancidity at long-term storage. Atmospheric venting through hydrophobic dust filter is the dominant pattern; nitrogen blanketing is an upgrade at high-purity ophthalmic + IV-vehicle service.

5. Field Handling Reality

Operator PPE. Pharmaceutical operators handling USP castor oil require standard pharmaceutical manufacturing PPE: cleanroom-grade gowning at sterile + cleanroom operations, safety glasses + lab coat + closed-toe shoes at non-cleanroom ingredient warehouse + bulk-receipt operations, nitrile gloves at all liquid-handling operations to prevent product cross-contamination + skin oil-exposure dermatitis (castor oil is generally non-irritating but extended-contact dermal exposure can defat skin and trigger contact dermatitis in sensitive individuals). Spill-response gear at the bulk-receipt area. No respirator required at any handling temperature; no splash-shield required beyond standard safety glasses.

Microbial Bioburden Control + Oxidative Stability. Castor oil's water-immiscible nature makes bacterial + mold growth uncommon in concentrated oil; the principal stability concern is oxidative rancidity + peroxide-value increase + free-fatty-acid increase + viscosity-shift over extended storage at elevated temperature + light + oxygen exposure. Bulk-storage best practice includes nitrogen blanketing where high-purity end-use is required, peroxide-value monitoring quarterly, scheduled tank-inspection for water-phase + sediment + color-change, and validated lot-release retest of stored material if storage exceeds the manufacturer-stated shelf-life.

Spill Response. Castor oil spill response is a fixed-oil cleanup: (1) deploy oil-only sorbent pads + booms (water-based sorbents do not absorb fixed oils efficiently), (2) collect into double-bagged poly waste for vegetable-oil + pharmaceutical-waste profiling and disposal under facility-specific waste streams (typically non-RCRA, non-hazardous, profiled for recycling or biofuel + bioethanol feedstock or incineration), (3) decontaminate spill area with degreaser + hot-water + detergent (castor oil's water-immiscibility and high viscosity make degreaser-based cleaning the appropriate decontamination route; oil residue requires multiple cleaning passes for full removal), (4) document spill volume + decontamination + containment integrity for the facility deviation + investigation system per 21 CFR 211.192.

Slip Hazard. Castor oil's extremely low coefficient of friction on hard floors creates a severe slip hazard; the high viscosity actually exacerbates the slip risk because the residue persists on floors longer than low-viscosity oils. Slip-resistant floor mats + secondary containment + immediate floor cleaning protocols are essential at the bulk-receipt staging area; pharmaceutical safety programs include castor-oil spill in the standard slip-trip-fall hazard inventory under OSHA 29 CFR 1910.22 General Walking-Working Surfaces.

Decontamination of Cross-Contamination Spills. Pharmaceutical manufacturing under 21 CFR 211.42 + 21 CFR 211.46 + 21 CFR 211.67 cleaning + cross-contamination prevention requires documented cleaning of any spill area + adjacent equipment + drains + transfer-piping returning to compendial-clean status. Castor oil's water-immiscibility, persistence, and oxidative-rancidity-after-residue character make spill-area decontamination demanding; multi-pass degreaser cleaning + residual-test-swab verification is the standard cross-contamination clearance protocol.

Allergen Awareness. Castor seed allergen content (Ricinus communis) is removed during refining; pharmaceutical castor oil is not an allergen risk in the formulation. However, occupational sensitization to castor seed dust at upstream agricultural + crushing operations is a documented health concern in castor-bean-processing regions (India, Brazil, China) and downstream pharmaceutical-grade refiners maintain occupational-health programs at upstream supplier qualification.

Talk to OneSource Plastics

Listed price covers tank + standard fitting package; LTL freight is quoted separately to your delivery ZIP. Call 866-418-1777, use our freight estimator, or try our chemical tank recommender to narrow material selection.